SCHEMBL23484654

SCHEMBL23484654

c1cc(C2CCC3(CC2)OCCO3)cc(N2CCCCC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.44
FAAH O00519 2/20 0.39
LGMN Q99538 1/20 0.38
AGXT P21549 1/20 0.38
HDAC4 P56524 1/20 0.37
RORC P51449 2/20 0.37
CYP3A4 P08684 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
EBP Q15125 1/20 0.36
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 1/20 0.34
L3MBTL3 Q96JM7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22817132 0.82 EBP (0.39) DHFREBP
SCHEMBL30228721 0.82 DHFR (0.52) DHFRFAAHAGXTHDAC4PRMT6
SCHEMBL29990735 0.82 DHFR (0.52) DHFRFAAHAGXTHDAC4PRMT6
SCHEMBL615270 0.81 L3MBTL1 (0.43) FAAHLGMNALDH1A1KDM4EMEN1
SCHEMBL23064612 0.81 DHFR (0.54) DHFRFAAHAGXTHDAC4PRMT6
SCHEMBL15305873 0.76 QDPR (0.47) DHFRFAAHHDAC4PRMT6ALDH1A1
SCHEMBL22817129 0.76 FAAH (0.48) DHFRFAAHAGXTHDAC4CYP3A4
SCHEMBL30817396 0.75 LGMN (0.43) DHFRLGMNRORCCYP3A4ALDH1A1
SCHEMBL22817128 0.74 FAAH (0.44) DHFRFAAHHDAC4CYP3A4PRMT6
SCHEMBL20010986 0.74 SLC6A2 (0.44) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT DHFR 693/4885FAAH 1807/4885LGMN 272/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT DHFR 693/4885FAAH 1807/4885LGMN 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.